Belsomra vs Dayvigo: Which Sleep Medicine Works Longer for Women?

Why the Drug Class Matters Before You Compare Doses

Belsomra and Dayvigo belong to the same drug class, dual orexin receptor antagonists (DORAs), but they are not interchangeable milligram for milligram. Understanding how they work in a female body is the starting point for any durability comparison.

Orexin (also called hypocretin) is a neuropeptide that keeps you awake. Both drugs compete with orexin at OX1R and OX2R receptors, quieting wakefulness signals rather than sedating the entire brain the way older benzodiazepines or Z-drugs do. This mechanism means they can, in principle, support more natural sleep architecture.

Why women's orexin signaling differs

Women's orexin neurons are influenced by estrogen and progesterone. Estrogen modulates OX1R expression in the hypothalamus, and progesterone has independent sedating properties that interact with GABAergic pathways adjacent to the orexin system. This means the same orexin-blocking dose may produce a different depth of sleep effect depending on where a woman is in her cycle or whether she is perimenopausal. This pharmacodynamic difference has not been formally studied in DORA trials, which is an honest gap in the evidence base that every prescriber should acknowledge.

How the two drugs differ chemically

Suvorexant has a half-life of roughly 12 hours. Lemborexant has a shorter mean half-life of approximately 17 to 19 hours in the general population, which seems counterintuitive until you look at active metabolite behavior. What matters clinically is that lemborexant's receptor-binding kinetics are faster on and faster off, which the SUNRISE-1 investigators proposed as one explanation for its somewhat cleaner morning performance at the 5 mg dose.

The Long-Term Durability Data, Head to Head

For most of the women asking this question, the core issue is not which pill works on night one. It is which one keeps working at month six, month nine, or year one without needing a dose increase, and without a tolerance cliff.

Suvorexant's 12-month trial (Herring et al., Lancet Neurology 2014)

The registration trial for suvorexant included a 12-month open-label safety extension in adults with chronic insomnia. Participants showed sustained reductions in subjective time to sleep onset and wake after sleep onset through month 12. There was no pharmacological dose escalation signal within the trial period, suggesting durability without tolerance. The study enrolled both men and women but did not publish sex-stratified efficacy outcomes, so whether women retained benefit equally over 12 months is extrapolated, not directly confirmed.

Lemborexant's SUNRISE-2 (12-month extension)

SUNRISE-2 was a Phase 3, randomized, double-blind, placebo-controlled trial that ran for 12 months in adults with insomnia disorder. Published data from its extension showed that lemborexant 5 mg and 10 mg maintained statistically significant improvements in subjective sleep onset latency and wake after sleep onset versus placebo throughout the study period. Discontinuation for lack of efficacy was low. Again, sex-stratified long-term data were not published as a primary endpoint.

SUNRISE-1: The only direct head-to-head trial

SUNRISE-1 (JAMA Network Open 2019) is the only randomized trial that put suvorexant and lemborexant in the same study. Over a one-month treatment period, lemborexant 5 mg and 10 mg were compared against suvorexant 20 mg (the highest approved dose) and placebo on polysomnographic endpoints in adults 55 years and older. Lemborexant 10 mg outperformed suvorexant 20 mg on sleep efficiency and wake after sleep onset at night. Lemborexant 5 mg was non-inferior to suvorexant 20 mg on most endpoints. The suvorexant 20 mg arm showed higher next-morning residual sleepiness than either lemborexant dose. The trial lasted only one month, so calling it a durability comparison overstates what it measured.

What one month of head-to-head data actually tells us

One month is enough to establish which drug has a faster and cleaner pharmacokinetic profile at the end of the night. It is not enough to tell you whether suvorexant's effect fades faster at month six than lemborexant's. For that, you have to compare each drug's own long-term arm against placebo and make an indirect inference. The indirect evidence favors lemborexant on sleep maintenance metrics, but the margin is modest and comes with a major caveat: the two long-term trials used different polysomnographic protocols and patient populations.

Women-Specific Efficacy Across Life Stages

No published DORA trial has used hormonal status as a primary stratification variable. What follows is a clinical framework built from mechanistic data, subgroup analyses, and clinical practice, not from a dedicated women's trial. Treat it as informed guidance, not settled science.

Reproductive years (roughly age 18 to 45)

If you have regular cycles, sleep disruption often clusters in the late luteal phase, the week before menstruation, when progesterone withdrawal reduces its GABAergic buffering effect. A DORA taken nightly may blunt this pattern more consistently than a Z-drug, which can cause rebound on nights you skip it. Neither suvorexant nor lemborexant has cycle-phase dosing data. The practical implication: if sleep is only disrupted in your luteal phase, a nightly Schedule IV controlled substance may be more than you need, and targeted behavioral or low-dose melatonin approaches deserve a first trial.

Trying to conceive

Both DORAs are contraindicated in pregnancy (see the pregnancy section below). If you are actively trying to conceive and your insomnia is severe enough to require medication, discuss a bridging plan with your prescriber before your next ovulation window. This is not a theoretical concern. Suvorexant has animal reproductive toxicity data, and lemborexant's developmental risk in humans is unknown.

Perimenopause (typically age 45 to 55, though onset varies widely)

This is where DORAs may offer the most meaningful benefit over other insomnia agents. Perimenopausal sleep disruption has two overlapping drivers: vasomotor symptoms (hot flashes and night sweats that fragment sleep) and an orexin-mediated shift in sleep architecture independent of hot flashes. A growing body of mechanistic evidence suggests that estrogen decline dysregulates orexin tone, which may explain why perimenopausal women often describe a qualitative change in their sleep, not just more awakenings.

A DORA addresses the orexin-mediated component directly. It does not treat vasomotor symptoms. If you are having five or more moderate-to-severe hot flashes per night, adding a DORA without also managing hot flashes is treating only half the problem. Menopause hormone therapy (MHT) and DORAs can be used together, and for many women in the transition, the combination is more effective than either alone, though this combination has not been studied in a randomized trial.

SUNRISE-1 enrolled adults 55 and older, which overlaps with the postmenopausal population. The trial did not report menopausal status or MHT use, so any claim that SUNRISE-1 directly validates DORA efficacy in perimenopausal women is a stretch.

Postmenopause

Sleep maintenance insomnia, the kind where you wake at 3 a.m. And cannot return to sleep, is the dominant complaint in postmenopausal women. This maps neatly onto what DORAs do best. Lemborexant's polysomnographic advantage over suvorexant on wake after sleep onset in the second half of the night, as shown in SUNRISE-1, may therefore be more clinically meaningful in this group than in younger women.

Older women also clear drugs more slowly. The FDA label for lemborexant notes that plasma exposure was approximately 34% higher in older adults than in younger adults. Suvorexant exposure is similarly elevated in older adults. Starting at the lowest approved dose in any woman over 65 is standard practice, and the 5 mg lemborexant dose is worth trialing before the 10 mg in this group.

Dosing Comparison at a Glance

| Feature | Suvorexant (Belsomra) | Lemborexant (Dayvigo) | |---|---|---| | Starting dose | 10 mg | 5 mg | | Max approved dose | 20 mg | 10 mg | | Half-life | ~12 hours | ~17 hours (parent); faster receptor off-rate | | Take with food? | Avoid high-fat meals; delays onset | Same caution applies | | Dose in older adults | 10 mg; titrate with caution | 5 mg preferred; data support this | | CYP3A4 interaction | Significant; halve dose with moderate inhibitors | Same enzyme; similar interaction profile | | Dose with CYP3A4 inhibitors | Reduce to 5 mg or avoid | Max 5 mg with moderate inhibitors |

Switching from Belsomra to Dayvigo: A Practical Guide

Some women ask their prescriber to switch after suvorexant stops feeling effective, or after experiencing residual morning grogginess on the 20 mg dose. Here is what the evidence and clinical practice support.

When switching makes clinical sense

• You are on suvorexant 20 mg and still waking for long stretches after 3 a.m.
• You are experiencing next-day sedation that affects driving or work concentration.
• Your insomnia pattern has shifted toward sleep maintenance rather than sleep onset, and you want the drug with the stronger polysomnographic data on wake after sleep onset in the second half of the night.

How to switch practically

There is no published washout protocol specific to DORA-to-DORA switching. Because both drugs work by the same mechanism and are Schedule IV controlled substances, a direct switch is pharmacologically reasonable. Stop suvorexant on the last night you take it, and start lemborexant at 5 mg the following night. Do not overlap them. Suvorexant's 12-hour half-life means it is mostly cleared within 48 hours, so accumulation is not a practical concern.

What you might notice in the first two weeks

Some women report that the first few nights on lemborexant feel lighter or shorter. This likely reflects the faster receptor off-rate rather than reduced efficacy. Give the 5 mg dose at least two weeks before deciding it is not working. If sleep onset is the remaining problem after the switch, ask your prescriber whether 10 mg is appropriate.

Pregnancy, Lactation, and Contraception

Both suvorexant and lemborexant are contraindicated in pregnancy. This is not an advisory note buried in fine print. It is the clinical position you need to know before you fill either prescription.

Suvorexant in pregnancy

Suvorexant has no adequate human pregnancy data. Animal studies at exposures above the therapeutic range showed decreases in offspring survival and body weight. The FDA labeling for suvorexant places it in the category of drugs where animal data signal risk and human data are insufficient. If you become pregnant while taking suvorexant, contact your prescriber immediately to discuss discontinuation.

Lemborexant in pregnancy

Lemborexant similarly lacks human pregnancy data. Animal reproductive studies showed effects on offspring development at doses exceeding human therapeutic exposure. Prescribers should ensure women of reproductive potential are using reliable contraception before starting either DORA.

Contraception requirement

Because insomnia is a chronic condition treated for months to years, and because both DORAs are Schedule IV substances taken nightly, a formal contraception discussion belongs at the prescribing visit. An unintended pregnancy would require immediate discontinuation and a conversation about first-trimester exposure risk, which is currently unknowable for either drug. Highly effective contraception (hormonal IUC, copper IUC, implant, or combined hormonal contraceptive) is the standard recommendation.

Hormonal contraception does not meaningfully alter CYP3A4 metabolism of either DORA at standard oral contraceptive doses, so the drug interaction profile does not change your contraceptive options.

Breastfeeding

Neither suvorexant nor lemborexant has published human milk transfer studies. Animal data for suvorexant show excretion in milk, though at low ratios. Until human lactation pharmacokinetic data exist, both drugs should be avoided during breastfeeding. If insomnia is severe in the postpartum period, cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment with the strongest evidence and no lactation risk. Short-term use of low-dose doxylamine or melatonin is a pharmacological alternative with a more established safety record in lactation, though data there are also limited.

Who Is a Good Candidate, and Who Should Look Elsewhere

Women who may benefit most from a DORA

• Postmenopausal women with sleep maintenance insomnia not fully controlled by MHT alone.
• Perimenopausal women whose hot-flash-related awakenings have been addressed but who still have orexin-driven early-morning waking.
• Women who have failed or cannot tolerate Z-drugs (zolpidem, eszopiclone) due to complex sleep behaviors, dependence, or morning grogginess.
• Women on stable non-interacting medications who need a nightly, non-habit-forming schedule.

Women who should approach DORAs with caution or try alternatives first

• Women actively trying to conceive. The contraindication window is too short and the exposure risk too uncertain.
• Women with severe depression. DORAs have a class warning about worsening depression and emergent suicidal ideation. This does not mean they are absolutely contraindicated in depression, but CBT-I should be the primary treatment and the prescribing clinician should be aware of your mental health history.
• Women with narcolepsy or cataplexy. DORAs are contraindicated in narcolepsy; blocking orexin in someone who is already orexin-deficient will worsen cataplexy.
• Women taking strong CYP3A4 inhibitors (such as clarithromycin, ritonavir, or ketoconazole). Both DORAs are extensively metabolized by CYP3A4, and co-administration is either contraindicated or requires significant dose reduction.
• Women with severe hepatic impairment. Both drugs accumulate in hepatic disease; suvorexant is not recommended and lemborexant requires dose reduction.

The Evidence Gap We Owe You Honesty About

Women have been enrolled in DORA trials, but hormonal status, menstrual phase, and menopausal staging have not been used as primary stratification variables in any published Phase 3 trial for either drug. The Herring et al. 2014 Lancet Neurology trial did not publish sex-stratified outcomes for the 12-month extension. SUNRISE-1 enrolled adults 55 and older, a group with high postmenopausal prevalence, but menopausal status was not reported. This means all guidance on DORA use across the female life span is drawn from mechanistic inference and clinical experience, not from a trial designed to answer that specific question.

That gap matters. An estrogen-replete 28-year-old with luteal-phase insomnia and a 61-year-old postmenopausal woman on no MHT are receiving the same labeled dose recommendations. We need hormone-stratified DORA trials. Until they exist, prescribers should titrate to effect at the lowest dose, reassess every 3 months, and consider whether the underlying hormonal driver has been addressed.

Frequently Asked Questions